Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06909604
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Overview
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Sponsor
Peking University Cancer Hospital & Institute
Phase
N/A
Contacts
Yannan Yuan (CONTACT)
gcp_yuanyn@bjcancer.org
01088197730
Xiaoyi Guo, PhD (CONTACT)
15833916752@163.com
010-88196495
ClinicalTrials.gov
NCT06909604Drug / Compound
HER2-BCH
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- HER2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA
Eligibility
Inclusion
- Patients with HER2 positive or low tumors;
- Receives neoadjuvant therapy
Exclusion
- Significant hepatic or renal dysfunction;
Share your feedback
Help us improve your experience